Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor
Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161
Extending cash runway through Q3 2025
https://finance.yahoo.com/news/arbutus-announces-pipeline-updates-dosing-201500319.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.